SCHEMBL29544265

SCHEMBL29544265

Cn1cc(B2OC(C)(C)C(C)(C)O2)c2ccccc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 1/20 0.43
IMPDH2 P12268 3/20 0.41
ALDH1A1 P00352 3/20 0.41
CDK2 P24941 2/20 0.41
CCNE2 O96020 1/20 0.41
CDK4 P11802 1/20 0.41
CCND1 P24385 1/20 0.41
CCNE1 P24864 1/20 0.41
KMT2A Q03164 3/20 0.39
MEN1 O00255 1/20 0.39
CRHBP P24387 1/20 0.39
CRHR2 Q13324 1/20 0.39
HTR2A P28223 1/20 0.39
LPL P06858 1/20 0.39
LIPG Q9Y5X9 1/20 0.39
NPSR1 Q6W5P4 1/20 0.38
GSK3B P49841 1/20 0.38
TP53 P04637 1/20 0.38
MAPT P10636 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL44373 1.00 GPR84 (0.43) GPR84IMPDH2ALDH1A1CDK2CCNE2
SCHEMBL16649616 0.81 BRD4 (0.46)
SCHEMBL29613202 0.81 BRD4 (0.46)
SCHEMBL31514219 0.80 LPL (0.36) LPLLIPG
SCHEMBL2216834 0.79 RHEB (0.39) ALDH1A1LPLLIPGMAPTKDM4E
SCHEMBL29827771 0.79 RHEB (0.39) ALDH1A1LPLLIPGMAPTKDM4E
SCHEMBL15548460 0.78 DYRK1A (0.48) GSK3B
SCHEMBL30132970 0.78 DYRK1A (0.48) GSK3B
SCHEMBL30132971 0.78 DYRK1A (0.48) GSK3B
SCHEMBL1356283 0.78 KDM4E (0.47) ALDH1A1CDK2KMT2AMEN1LPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136576-A1 Heterocyclic Compounds and Uses Thereof ACEA Therapeutics, Inc. (US) 2025-05-01 US disclosed
EP-4518858-A1 INHIBITORS OF TAU PROTEINS Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DE) 2025-03-12 EP disclosed
WO-2023213850-A1 INHIBITORS OF TAU PROTEINS DEUTSCHES ZENTRUM FÜR NEURODEGENERATIVE ERKRANKUNGEN E. V. (DZNE) (DE) 2023-11-09 WO disclosed
WO-2023287783-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF ACEA Therapeutics, Inc. (US) 2023-01-19 WO disclosed
EP-3997088-A1 DERIVATIVES OF 4-(IMIDAZO[L,2-A]PYRIDIN-3-YL)-N-(PYRIDINYL)PYRIMIDIN- 2-AMINE AS THERAPEUTIC AGENTS Aucentra Therapeutics Pty Ltd (AU) 2022-05-18 EP disclosed
CN-114269742-A Derivatives of 4- (imidazo [1,2-a ] pyridin-3-yl) -N- (pyridinyl) pyrimidin-2-amines as therapeutic agents 常州千红生化制药股份有限公司 2022-04-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136576-A1 Heterocyclic Compounds and Uses Thereof CHEK2, CDK2, CDK1 GPR84 4063/4885IMPDH2 2548/4885ALDH1A1 1877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.